Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been unthinkable a decade ago, and target the US first.

In the present work we focus on the key function of N condensing viral RNA into ribonucleoprotein particles (RNPs) for viral assembly. Lacking high-resolution structural information, biochemical and ...